J&J's hep C drug gets German thumbs up; Ex-Sanofi chemist admits to stealing trade secrets;

@FiercePharma: 2004 J&J memo asked reps to "flood clinics with Risperdal stuff" to boost off-label scripts for kids, TX says--Bloomberg. Story | Follow @FiercePharma

> Germany's drug-review panel concluded that Johnson & Johnson's ($JNJ) hepatitis C drug Incivo beats existing drugs at treating the disease, a key step toward price-setting under the country's new system. News

> A former Sanofi ($SNY) chemist pleaded guilty to stealing trade secrets and putting them up for sale in China, prosecutors said. Item

> Bosnia's leading drugmaker, Bosnalijek, predicts it will double profits this year, on top of a 42% increase in profits for 2011. Story

> XOMA ($XOMA) said it acquired U.S. rights to Servier's Aceon brand of blood-pressure products. News

> Savient Pharmaceuticals ($SVNT) has tapped a former SVP at Bristol-Myers Squibb ($BMY), David Veitch, as its new European president. Article

> Zacks maintained its "outperform" recommendation on Celgene ($CELG) after the company released "impressive" preliminary results from the fourth quarter and full year 2011. Item

> Deutsche Bank raised its price targets on Eli Lilly ($LLY) and Pfizer ($PFE), pegging Lilly at $40 and Pfizer at $23, an increase of $2 in each case. Report

Biotech News

@FierceBiotech: Quintiles is pumping $4.6M into UK's Oxford Cancer Biomarkers as part of the CRO's push in personalized medicine. Article | Follow @FierceBiotech

@JohnCFierce: R&D taking a hit in Takeda layoffs, Bloomberg reports Konstanz, Germany facility affected. Anyone heard about other sites? Item | Follow @JohnCFierce

@FierceMedDev: GE ($GE) selects Bionime to launch innovative diabetes solutions. Release | Follow @FierceMedDev

@MarkHFierce: U.K. scientists are adapting a chemo drug to attach to other pills so it can be delivered by capsule or tablet. More | Follow @MarkHFierce

> Takeda to axe 2,800 workers, consolidate R&D in global restructuring. News

> Atlas-backed upstart grabs $21M A round for RNA work. Story

> Columbia shares plunge after FDA staffers blast birth gel app. Article

Drug Delivery News

> Kedem pursues version of Novartis' Gleevec that dissolves under tongue. Item

> 'Smart' nanotech may help treat Type 1 diabetes. More

> Genentech pursues sustained-delivery version of blockbuster eye drug Lucentis. Story

Medical Device News

> Boston Sci boasts of positive study results with Epic stent system. Article

> Ventana, Bayer to collaborate on companion Dx for cancer. News

> Blood test may help detect pancreatic cancer early. Item

> Covidien recalls device linked to 3 deaths during thoracic surgery. News

Biomarkers News

> Researchers inch closer to stomach cancer blood tests. Story

> Qiagen signs diagnostic biomarker deals. Article

> Biomarkers could improve treatment of neuroendocrine tumors. More

> Teams closing in on gene behind form of muscular dystrophy. Item

> Biomarkers making an earache less of a headache. Story

And Finally... Study finds genetic Alzheimer's risk might be mitigated by exercise. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.